Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩1,759,000.00
Day range
₩1,700,000.00 - ₩1,795,000.00
Year range
₩982,000.00 - ₩1,987,000.00
Market cap
78.69T KRW
Avg Volume
62.17K
P/E ratio
49.31
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 1.29T | 2.35% |
Operating expense | 144.00B | -56.91% |
Net income | 510.00B | 58.63% |
Net profit margin | 39.66 | 54.98% |
Earnings per share | — | — |
EBITDA | — | — |
Effective tax rate | 21.22% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.46T | 9.37% |
Total assets | 11.06T | -36.20% |
Total liabilities | 3.61T | -43.87% |
Total equity | 7.45T | — |
Shares outstanding | 46.29M | — |
Price to book | 10.93 | — |
Return on assets | — | — |
Return on capital | — | — |
Cash Flow
Net change in cash
| (KRW) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 510.00B | 58.63% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Founded
2011
Website
Employees
4,770
